secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001619856-25-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO
--------------------------------------------------------------------------------

- Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.
- CB-010 ANTLER and CB-011 CaMMouflage Phase 1 data expected H1 2025; CB-010 pivotal Phase 3 planned H2 2025 pending HLA matching.
- CB-012 AMpLify Phase 1 in r/r AML: dose level 3 completed with no DLTs; enrolling dose level 4.
- Sri Ryali appointed CFO; $281M cash expected to fund operations into H2 2026.
- CB-012 granted FDA Fast Track and Orphan Drug designation for r/r AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/0001619856-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/crbu-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer